Abstract:The hydrogenation of complex pharmaceutical intermediate, rac-sertraline imine has been optimized as a continuous flow process utilizing a palladium/calcium carbonate (Pd/CaCO 3 ) catalyst and hydrogen in supercritical carbon dioxide (scCO 2 ). Superior levels of selectivity were obtained in the flow system possibly attributable to the heat transfer properties of scCO 2 which help to remove excess heat from the catalyst surface.Keywords: carbon dioxide; diastereoselectivity; hydrogenation; sertraline; supercritical fluidsThe excessive use of organic solvents in synthesis, purification and cleaning is the largest single contributor to overall chemical waste in the pharmaceutical industry. Therefore, a new technology that minimizes the use of organic solvents will help make pharmaceutical and fine chemical synthesis more sustainable. Supercritical fluids (SCFs) and, in particular, supercritical CO 2 (scCO 2 ), have emerged as alternative green solvents which can help the pharmaceutical industry attain this goal. [1,2] For instance, SCF chromatography [3,4] and SCF extraction [5,6] have proved to be powerful tools for the separation of active pharmaceutical ingredients (APIs) from complex mixtures. scCO 2 has also more recently been applied to anti-solvent precipitation of drug particles from solution.[7-10] scCO 2 is highly suitable for pharmaceutical processing because it is non-toxic and has relatively mild critical parameters (T c = 31 8C, P c = 74 bar) so that the advantages of near-critical and scCO 2 can be achieved, whilst operating at relatively low temperatures where degradation of sensitive molecules is unlikely.The application of scCO 2 as a solvent for the synthesis of pharmaceuticals has not yet been fully realized. This is because synthetic research in scCO 2 has focused largely on model substrates and compounds relevent to the bulk and fine chemicals industry. [11][12][13] This article explores the use of scCO 2 as a solvent for the hydrogenation of a complex pharmaceutical intermediate, [4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalenyidene]methylamine, also known as racsertraline imine 1.(4S)-Sertraline imine 1a is an intermediate in the synthesis of cis-(1S,4S)-sertraline hydrochloride 2, marketed under the name, Zoloft (Scheme 1), a multi-billion dollar drug developed originally by Pfizer for the treatment of depression and other anxiety related disorders. [14,15] Today Zoloft is manufactured in relatively few steps by first reacting 1-naphthol, 3, and 1,2-dichlorobenzene, 4, with aluminium chloride to provide the racemic intermediate ketone. Simulated moving bed (SMB) chromatography is then used to separate efficiently the (4S)-and (4R)-enantiomers. Enantiomerically pure (4S)-ketone is then reacted with methylamine to afford the imine 1a. Diastereoselective hydrogenation puts in the second chiral centre to afford (4S)-sertraline before conversion to the hydrochloride salt 2 (Scheme 1).We chose to study the hydrogenation of imine 1a in scCO 2 for a number of reasons. It has both regio-a...